UK CROs extend preclinical cancer partnership

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology, Pharmaceutical industry, Cancer

Preclinical Oncology Services Limited (Precos) will to work with discovery services firm Argenta Discovery on cancer drug development projects under a revised collaboration agreement announced late yesterday.

The deal, financial terms of which were not disclosed, extends Precos provision of oncology focused drug discovery, modelling and cell line development services by five years.

The two UK companies teamed up to provide contract cancer drug development in February 2009​, with the idea being that the combination of Argenta’s range of chemistry services with Precos’ capabilities would create a broad offering.

Argenta managing director John Montana welcomed the deal extension and suggested the partnership will continue to provide benefits for pharmaceutical industry customers.

Through this alliance our pharmaceutical clients are able to benefit from seamless access to Precos' models and scientists. We are excited to have PRECOS as a key extension of our team, working in partnership with our experienced oncology drug discovery scientists.​"

This was echoed by Precos CSO Sue Watson, who said: "Argenta has an excellent reputation for providing first class contract drug discovery services to the global pharmaceutical industry; especially in oncology​.”

Rapid growth

Belgium, where Argenta’s owner Galapagos NV is based, has proved to be an important source of business for Precos in recent months.

In November Precos, which was only spun out from the University of Nottingham last summer, signed a multi year global services agreement with Johnson & Johnson’s Belgium-headquartered Janssen Pharmaceutica unit.

That deal will see Precos supply Janssen with clinical tumour material and provide model development and target validation and candidate efficacy analysis service for its discovery and biomarker programmes.

Related topics: Bio Developments

Follow us


View more